When Hph-1-ctCTLA-4 was administered through the joint skin area of the CIA mice, arthritis clinical score and incidence, and histology of the joint area, were greatly improved

When Hph-1-ctCTLA-4 was administered through the joint skin area of the CIA mice, arthritis clinical score and incidence, and histology of the joint area, were greatly improved. collagen-specific antibody levels were significantly reduced, and the numbers of activated T cells and infiltrating granulocytes were substantially decreased. These results demonstrate that systemic or transdermal application of a cell-permeable form of the cytoplasmic domain name of CTLA-4 offers an effective therapeutic approach for autoimmune diseases such as rheumatoid arthritis. Keywords:autoimmune disease, costimulatory molecule Rheumatoid arthritis (RA) is usually a chronic, systemic inflammatory disorder that leads to progressive joint destruction (1). Hallmarks of RA are joint inflammation, proliferation of synovial cells, and attachment and invasion of synovial fibroblasts into adjacent cartilage and bone (2,3). Cumulative evidence has indicated that CD4+T cell-mediated autoimmune responses play a critical role in the pathogenesis of RA, in conjunction with activation of B cells and macrophages that infiltrate the synovium (4,5). Recent Mmp8 biological therapies against IL-1, IL-6, or TNF- have demonstrated promising effects against progressive joint destruction (68). However, the clinical use of these therapies has been limited because of several issues, including side effects and the increase of therapy-insensitive patients. Recently, several Ribocil B reports demonstrated that regulation of costimulatory signaling in the T cell is an important target for treatment of autoimmune diseases such as arthritis (9,10). CTLA-4 is an activation-induced surface molecule Ribocil B on T cells and is essential for the unfavorable regulation of T cell activation; its inhibitory effects can be accomplished either by competition with CD28 for their ligands B71 and -2 or by transmission of negative signals through its intracellular domain (11,12). The cytoplasmic domain name of CTLA-4 (ctCTLA-4), which contains a tyrosine phosphorylation motif, has been found to be 100% conserved among different species, suggesting that this domain name is critical for CTLA-4 functions (13,14). In addition, there are several splicing variants of CTLA-4, including full-length CTLA-4, soluble CTLA-4 that lacks the transmembrane domain name, ligand-independent CTLA-4 (liCTLA-4) that lacks the extracellular domain name, and only the cytoplasmic domain name of CTLA-4 (15). However, the function of these spicing variants in various T cell subsets is not fully comprehended. Intracellular delivery of many therapeutic and diagnostic brokers can be challenging because the plasma membrane forms a formidable barrier against entry of biomolecules. The discovery of the protein transduction domain name (PTD) has made it possible to transduce therapeutically active brokers into living cells (1618). PTDs such as Tat, Antp, Vp22, MTS, Pep-1, and R7 have protein transduction efficiency good enough to be used in protein drug development; however, these PTDs are either of virus or of Drosophila origin, or are generated by assembling different peptide sequences (1924). In our previous report, we identified a novel human PTD, Hph-1, and Hph-1-PTD has efficient protein transduction efficiency Ribocil B and can deliver therapeutic protein to prevent airway inflammation via an intranasal route (25). In this study, we describe possible mechanisms for the inhibitory function of the cell-permeable cytoplasmic domain name of CTLA-4 (Hph-1-ctCTLA-4) in T cell activation and the therapeutic effects via systemic or transdermal application in the collagen type II (CII)-induced arthritis (CIA) modelin vivo. These results demonstrate that blockade of the T cell costimulation pathway by Hph-1-ctCTLA-4 prevents arthritic symptoms effectively and provides preclinical support for the potential therapeutic efficacy of Hph-1-ctCTLA-4 against autoimmune diseases like human RA via systemic or transdermal administration. == Results == == Regulation of T Cell Function by Hph-ctCTLA-4. == To evaluate how ctCTLA-4 regulates T cell activation, a cell-permeable form of ctCTLA-4 (Hph-1-ctCTLA-4), the tyrosine mutant form of ctCTLA-4 (Hph-1-ctCTLA-4YF), and ctCTLA-4 without the Hph-1-PTD were designed as previously described (25). We purified these proteins under denaturing conditions and the purified proteins were characterized by Western blot analysis with anti-HA antibody Ribocil B [supporting information (SI) Fig. S1]. In mouse splenocytes, Hph-1-ctCTLA-4 strongly inhibited secretion of inflammatory cytokines, including IFN-,.